Repository logo
 
Publication

High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer

2018Journal article Open access
Simple item page
dc.contributor.authorLobo, João
dc.contributor.authorRodrigues, Ângelo
dc.contributor.authorAntunes, Luís
dc.contributor.authorPinho dos Santos Graça, Maria Inês
dc.contributor.authorRamalho-Carvalho, João
dc.contributor.authorQuintela Vieira, Ana Filipa
dc.contributor.authorMartins, Ana Teresa
dc.contributor.authorOliveira, Jorge
dc.contributor.authorJerónimo, Carmen
dc.contributor.authorHenrique, Rui
dc.date.accessioned2019-06-27T12:10:10Z
dc.date.available2019-06-27T12:10:10Z
dc.date.issued2018
dc.description.abstractOvertreatment is a major concern in patients with prostate cancer (PCa). Prognostic biomarkers discriminating indolent from aggressive disease in prostate biopsy are urgently needed. We aimed to evaluate the prognostic value of Ki67, EZH2, LSD1, and SMYD3 immunoexpression in diagnostic biopsies from a cohort of PCa patients with long term follow-up. A series of 189 consecutive prostate biopsies diagnosed with PCa (1997–2001) in a cancer center was included in the study, with follow-up last updated in November 2016. Biopsies were reviewed and graded according to 2016 WHO criteria. Immunohistochemistry was performed in the most representative block. Nuclear staining was assessed using digital image analysis. Study outcomes included disease-specific, disease-free, and progression-free survival. Statistical analysis was tabulated using SPSS version 22.0. Survival curves and hazard ratios (HRs) were estimated using Kaplan-Meyer and Cox-regression models, respectively. Statistical significance was set at P<0.05. The proportion of patients who completed the study was 177/189 (94%). In univariable analysis, high Ki67, EZH2, and SMYD3 immunoexpression associated with significantly worse disease-specific survival (HR = 1.86, 95% CI: 1.05–3.29; HR = 1.87, 95% CI: 1.10–3.27; HR = 2.68, 95% CI: 1.02–7.92). In multivariable analysis, the 3 biomarkers displayed significantly worse DSS adjusted for CAPRA score (HR = 1.78, 95% CI: 1.01–3.16; HR = 1.93, 95% CI: 1.12–3.32; HR = 2.71, 95% CI: 1.04–7.10). Among patients with low/intermediate risk CAPRA score, high Ki67 immunoexpression identified those more prone to experience disease recurrence (HR = 9.20, 95% CI: 1.27–66.44) and progression (HR = 2.97, 95% CI: 1.05–8.43). High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with PCa, at diagnosis. This might assist in discriminating indolent from aggressive PCa, improving treatment selection.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationLobo, J., Rodrigues, Â., Antunes, L., Graça, I., Ramalho-Carvalho, J., Vieira, F. Q., Martins, A. T., Oliveira, J., Jerónimo, C., & Henrique, R. (2018). High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 36(4), 161.e7-161.e17. https://doi.org/10.1016/j.urolonc.2017.10.028
dc.identifier.doi10.1016/j.urolonc.2017.10.028pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.22/14101
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1078143917305653?via%3Dihubpt_PT
dc.subjectBiomarkers, Tumorpt_PT
dc.subjectBiopsypt_PT
dc.subjectImmunohistochemistrypt_PT
dc.subjectKi-67 Antigenpt_PT
dc.subjectProstatept_PT
dc.subjectProstatic Neoplasmspt_PT
dc.titleHigh immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage161.e17pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage161.e7pt_PT
oaire.citation.titleUrologic Oncology: Seminars and Original Investigationspt_PT
oaire.citation.volume36pt_PT
person.familyNamePinho dos Santos Graça
person.familyNameQuintela Vieira
person.givenNameMaria Inês
person.givenNameAna Filipa
person.identifier.orcid0000-0003-1383-4242
person.identifier.orcid0000-0003-0130-7664
person.identifier.scopus-author-id6505981373
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication8316e6ce-cc0a-41e6-90ab-910c93868670
relation.isAuthorOfPublication47123d10-a0ed-47cc-a751-721489a13446
relation.isAuthorOfPublication.latestForDiscovery8316e6ce-cc0a-41e6-90ab-910c93868670

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ART_InêsGraça_2018.pdf
Size:
2.09 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESS - APCT - Artigos
ESS - CQB - Artigos